BioNexus Gene Lab (BGLC) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MDxHealth SA is the larger company by market cap ($55.4 million vs $3.7 million), about 15.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BGLC | MDXH |
|---|---|---|
| Share price | $1.25 | $0.5805 |
| Market cap | $3.66M | $55.39M |
| 1-day change | -7.24% | -3.22% |
| YTD return | — | -83.20% |
| 1-year return | — | -87.40% |
| EPS (TTM) | $-1.26 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.89 | $5.33 |
| 52-week low | $1.07 | $0.40 |
| Distance from 52-week high | -78.78% | -89.11% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +210.08% |
| Average volume | 11.08K | 5.70M |
| Shares outstanding | 2.93M | 95.42M |
| Employees | 19 | 364 |
| Sector | Basic Materials | Healthcare |
| Industry | Specialty Chemicals | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDxHealth SA is about 15.1 times larger than BioNexus Gene Lab by market value ($55.39M vs $3.66M).
- The two companies sit in different sectors: BioNexus Gene Lab in Basic Materials and MDxHealth SA in Healthcare.
About BioNexus Gene Lab
BGLC stock →BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
Basic Materials · Specialty Chemicals · 19 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Healthcare · Diagnostics & Research · 364 employees
BGLC vs MDXH FAQ
Which is bigger, BioNexus Gene Lab or MDxHealth SA?
MDxHealth SA (MDXH) is larger, with a market capitalization of $55.39M compared with $3.66M for BioNexus Gene Lab (BGLC).
Are BioNexus Gene Lab and MDxHealth SA in the same industry?
No. BioNexus Gene Lab is in the Basic Materials sector, while MDxHealth SA is in Healthcare.